Published on : Jun 19, 2018
Albany, New York, June 19, 2018: The prevalence of neurological disorders on the global level has enhanced over the past few years. It has been recorded by the World Health Organization (WHO) that more than 1 billion people on the global scale suffered from neurological disorders, such as stroke, epilepsy, Alzheimers disease, Parkinsons disease (PD), glaucoma and brain injuries. As a method to control such occurrences, the implementation of neuroprotective agents is majorly practiced as a therapeutic option. To study the market for neuroprotective agents on the global front, a new research study has been published by Market Research Hub (MRH). This research report is titled “Neuroprotective Agents: Therapeutic Applications and Global Markets”, which discourses knowledge about the causes of neurological disorders and their treatment methods.
Neuroprotection is basically an approach concerned with the treatment of neurological disorders with the help of therapies which are developed by learning from the brains personal tools to protect nerve cells from getting damaged, degenerated and dead. Our human brain is capable of promoting growth, survival as well as differentiation to acclimate to sudden changes, disease and trauma. In the global markets, neuroprotective agents include gene therapies, small molecule drugs, therapeutic monoclonal antibodies, cell therapies and other agents. The report covers the global market highlighting small molecule drugs, gene and cell therapies, monoclonal antibodies and other biotechnology products which are approved or being developed for the treatment of neurological disorders.
The report includes several sections that offer a better insight about the neuroprotective agents market. A deeper analysis about different technological advancements in the sector have also been included in the report. Readers can further learn about antisense agents, antioxidants, anti-Parkinson's agents, anti-angiogenic agents, blood thinning agents, ocular hypotensives and thrombolytics.
Considering the geographical market presence, the U.S. has an average of more than 1.5 million people who suffer from a traumatic central nervous system (CNS) injury every year. This count majorly consists of young adults and elderly people. The concerned reasons includes falls, accidents, falls, sports- and work-related injuries, self-harm and combat. It is vital to note that, one-third of injury-related demises in the U.S. are due to traumatic brain injuries, which also tends to cause physical disabilities, neurodegenerative diseases and cognitive disorders. The research report is a useful data source since it includes 39 tables as well as profiles of key companies functioning in the global neuroprotective agents market. Bayer Healthcare, Glaxosmithkline Plc, Eisai Inc., Merck Serono S.A., Teva Pharmaceutical Industries Ltd. and Novartis Ag are the prime companies mentioned in the report.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1823511
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com